Arax Advisory Partners
RVMD icon

Arax Advisory Partners’s Revolution Medicines RVMD Stock Holding History

Arax Advisory Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.02M Buy
4,979
+2,144
+76% +$425K 0.01% 1310
2026
Q2 		$531K Buy
2,835
+2,666
+1,578% +$389K ﹤0.01% 1602
2026
Q1 		$16.4K Sell
169
-305
-64% -$30.8K ﹤0.01% 2201
2025
Q4 		$37.8K Buy
+474
New +$31.1K ﹤0.01% 1763
2025
Q1 		– Sell
-31
Closed -$1.36K – 2992
2024
Q4 		$1.36K Hold
31
– – ﹤0.01% 2099
2024
Q3 		$1.41K Hold
31
– – ﹤0.01% 2154
2024
Q2 		$1.2K Buy
+31
New +$1.16K ﹤0.01% 2117

Other funds holding RVMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Arax Advisory Partners's RVMD Position: Q3 2026 in Review

Arax Advisory Partners increased its Revolution Medicines (RVMD) stake by 76% in Q3 2026, buying an estimated $425K and bringing the position to 4,979 shares worth $1.02M. The position accounts for 0.01% of the portfolio, ranked #1310.

Arax Advisory Partners first reported a position in RVMD in Q2 2024 and has held it in 7 quarters since. 488 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

  • Arax Advisory Partners held 4,979 shares of Revolution Medicines worth $1.02M as of Q3 2026.
  • Arax Advisory Partners bought 2,144 Revolution Medicines shares in Q3 2026, an estimated $425K.
  • Revolution Medicines made up 0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #1310 holding.
  • Arax Advisory Partners first reported a position in Revolution Medicines in Q2 2024 and has held it in 7 quarters since.
  • 488 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.